Literature DB >> 7636512

Is the lifetime risk of depression actually increasing?

G E Simon1, M VonKorff, T B Ustun, R Gater, O Gureje, N Sartorius.   

Abstract

Data from an international study of psychological problems in primary care were examined for evidence of increasing depression risk. At 15 sites, patients aged 15-65 (n = 26,421) were screened with the GHQ-12 and a stratified random sample (n = 5603) selected for psychiatric assessment (Composite International Diagnostic Interview). Initial analyses agreed with earlier cross-sectional studies, finding higher depression risk and earlier onset in recent birth cohorts. Additional analyses suggested that methods effects may explain these findings. First, apparent prevalence increases were nonspecific with similar trends seen across all study sites and for all disorders examined. Second, reporting patterns suggested significant under-counting of past depressive episodes. Respondents of all ages typically reported first onset of depression during the last 5 years. Reported lifetime prevalence was only 2.02 times current prevalence. These findings suggest that depression risk is not rapidly increasing and that true lifetime prevalence is much higher than estimated by cross-sectional surveys.

Entities:  

Mesh:

Year:  1995        PMID: 7636512     DOI: 10.1016/0895-4356(95)00010-2

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  18 in total

1.  Re: silent epidemic of depression in women in the middle East and north Africa region.

Authors:  Zena Al-Sharbati
Journal:  Sultan Qaboos Univ Med J       Date:  2009-12-19

2.  Preliminary long-term follow-up of Mindfulness-based cognitive therapy-induced remission of depression.

Authors:  Krishna Munshi; Stuart Eisendrath; Kevin Delucchi
Journal:  Mindfulness (N Y)       Date:  2013-12-01

3.  A dimensional liability model of age differences in mental disorder prevalence: evidence from a national sample.

Authors:  Nicolas Hoertel; Kibby McMahon; Mark Olfson; Melanie M Wall; Jorge Mario Rodríguez-Fernández; Cédric Lemogne; Frédéric Limosin; Carlos Blanco
Journal:  J Psychiatr Res       Date:  2015-03-28       Impact factor: 4.791

4.  Demographic correlates of DSM-IV major depressive disorder among older African Americans, Black Caribbeans, and non-Hispanic Whites: results from the National Survey of American Life.

Authors:  María P Aranda; David H Chae; Karen D Lincoln; Robert Joseph Taylor; Amanda Toler Woodward; Linda M Chatters
Journal:  Int J Geriatr Psychiatry       Date:  2011-10-28       Impact factor: 3.485

Review 5.  Sertraline. A pharmacoeconomic evaluation of its use in depression.

Authors:  R Davis; M I Wilde
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

6.  Lifetime prevalence estimates of major depression: an indirect estimation method and a quantification of recall bias.

Authors:  Michelle Elisabeth Kruijshaar; Jan Barendregt; Theo Vos; Ron de Graaf; Jan Spijker; Gavin Andrews
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

7.  Has 'lifetime prevalence' reached the end of its life? An examination of the concept.

Authors:  David L Streiner; Scott B Patten; James C Anthony; John Cairney
Journal:  Int J Methods Psychiatr Res       Date:  2009-12       Impact factor: 4.035

8.  Age of onset of life-time mental disorders and treatment contact.

Authors:  Janhavi Ajit Vaingankar; Gurpreet Rekhi; Mythily Subramaniam; Edimansyah Abdin; Siow Ann Chong
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-10-18       Impact factor: 4.328

9.  How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment.

Authors:  T E Moffitt; A Caspi; A Taylor; J Kokaua; B J Milne; G Polanczyk; R Poulton
Journal:  Psychol Med       Date:  2009-09-01       Impact factor: 7.723

10.  Mental disorders in primary care in Israel: prevalence and risk factors.

Authors:  Neil Laufer; Nelly Zilber; Pablo Jecsmien; Binyamin Maoz; Daniel Grupper; Haggai Hermesh; Royi Gilad; Abraham Weizman; Hanan Munitz
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-01-04       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.